Flex Pharma, Inc.
-85%
est. 2Y upside i
Rank
#3550
Sector
Biotechnology
Est. Liquidity
~3Y
Data Quality
Data: LowDecoy Therapeutics (formerly Flex Pharma/Salarius Pharmaceuticals) presents a highly speculative equity opportunity.
Last updated: March 10, 2026
The new AI-enabled IMP3ACT platform for peptide-conjugate therapeutics gains significant traction, securing substantial non-dilutive funding (e.g., BARDA) and positive early clinical data for its lead antiviral or oncology candidate. This could attract a major pharmaceutical partnership or a significant follow-on investment, pushing the valuation to ~$16.88M (4x current market cap) within two years, representing a substantial percentage gain from the current low base.
Decoy Therapeutics makes slow but steady progress with its preclinical and early clinical programs, but faces ongoing capital challenges and market skepticism. The company maintains its Nasdaq listing through further compliance efforts and modest capital raises, but no major value-creating catalysts emerge. Valuation sees a modest increase to ~$5.06M (20% above current market cap) as the market awaits more definitive clinical data.
Decoy Therapeutics fails to achieve critical clinical milestones, experiences further significant dilution through additional stock offerings, or is unable to secure sufficient funding for its pipeline. Continued Nasdaq non-compliance leads to delisting, and the severe preference stack (over $86M in prior funding) effectively wipes out common stock value, resulting in a -90% loss for common shareholders.
Preference Stack Risk
severeInvestors hold over $86M in liquidation preferences (based on Flex Pharma's total funding, likely higher for the combined entity) ahead of common stock, significantly exceeding the current ~$4.22M market capitalization.
Dilution Risk
highThe company has a history of public offerings, warrant issuances, and reverse stock splits, indicating a high likelihood of further dilution to fund ongoing operations and clinical development.
Secondary Liquidity
noneGiven the extremely low market capitalization and ongoing financial instability, there is no indication of active secondary markets or tender offers for employee equity.
Questions to Ask at the Interview
Strategic questions based on Flex Pharma, Inc.'s data — designed to show you've done your homework.
- 1
“Given the recent pivot to the IMP3ACT peptide-conjugate platform and the focus on antivirals and GI cancers, how do you see Decoy Therapeutics differentiating itself from larger pharmaceutical companies and other biotech firms already active in these highly competitive therapeutic areas?”
- 2
“The company has faced Nasdaq compliance challenges and executed multiple reverse stock splits. What is the long-term strategy to ensure sustained compliance and build investor confidence, particularly regarding the Equity Standard Requirement?”
- 3
“For an employee considering equity compensation, what is the company's perspective on potential liquidity events within a 2-year to 5-year horizon, and how does the current capital structure, including any liquidation preferences, impact common stock holders?”
Community
Valuation Sentiment
Our model estimates -85% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.